# Zee Entertainment Enterprises Ltd.

# Sony calls off merger with ZEEL

## How it all started?

On 21<sup>st</sup> December 2021, Zee Entertainment Enterprises Ltd. (ZEEL) entered into a merger cooperation agreement with Culver Max Entertainment Pvt. (CMEPL), whose operating name is Sony Pictures India Ltd. and Bangla Entertainment Pvt. Ltd. (BEPL). The scheme of arrangement was approved by the NCLT, Mumbai bench, on 11<sup>th</sup> August 2023.

# ZEEL exercised the right to enter negotiations

As per the terms of the agreement, ZEEL, on 17<sup>th</sup> December 2023, announced that it has exercised its right to require CMEPL and BEPL to enter negotiations for a period of 30 days to arrive at a mutual agreement of the end date for completion of the transaction as per the terms of MCA.

### Termination of the merger

During the 30-day period to conduct good-faith negotiations, interested parties failed to arrive at a consensus. The clarifications issued by the Company mention that Mr. Punit Goenka, MD & CEO of ZEEL, was ready to step down in the interest of the merger and that ZEEL proposed an extension of a maximum of six months for the consummation of the transaction. However, CMEPL did not provide any counter-proposal for an extension but rather chose to terminate the merger.

### Other demands of CMEPL

Apart from terminating the merger cooperation agreement, CMEPL and BEPL have put forth a demand seeking termination fees of \$90 Mn on account of alleged breaches of the terms of MCA by ZEEL. The Company denies all the assertions raised by CMEPL and BEPL on the alleged breaches under the terms of MCA, including their claims for the termination fee.

### ZEEL's reply to CMEPL and BEPL

On 24<sup>th</sup> January 2023, ZEEL informed stock exchanges that they had issued a reply to CMEPL and BEPL and disclosed important contents of the same. In its reply, ZEEL has denied any breach of obligations under the terms laid out by the MCA. In addition to this, the Company also informed counterparties that their claim for termination fee is legally untenable and baseless.

Counterparties were also communicated that it's them who have defaulted on their obligations to give effect to the scheme of merger sanctioned by the NCLT. Over and above this, ZEEL asked CMEPL and BEPL to immediately withdraw the termination and confirm that they will perform their obligations to implement the merger scheme sanctioned by the NCLT.

The filing also mentioned that ZEEL had approached the NCLT, Mumbai bench seeking directions to implement the merger scheme and has also initiated appropriate legal action to contest the claims made by CMEPL and BEPL in the arbitration proceedings before the Singapore International Arbitration Center (SIAC).

# Merger termination will leave ZEEL financially weak

The merger between ZEEL and CMEPL would have created a mega entertainment entity with ~70-75 channels.

# 1<sup>st</sup> February 2024

# NEUTRAL

CMP Rs. 170 TARGET Rs. 174 (+2.4%)


### **Company Data**

Bloomberg Code	Z IN
MCAP (Rs. Mn)	1,63,370
O/S Shares (Mn)	961
52w High/Low	300 / 153
Face Value (in Rs.)	1
Liquidity (3M) (Rs. Mn)	6,911

# Shareholding Pattern %

	Dec-23	Sep-23	Jun-23
Promoters	3.99	3.99	3.99
FIIs	28.19	35.00	33.40
DIIs	43.57	42.22	40.77
Non- Institutional	24.25	18.79	21.85

ZEEL vs Nifty



	ZEEL	NIFTY		
Jan, 21	Jan, 22	Jan, 23	Jan, 24	

Source: Keynote Capitals Ltd.

### Key Financial Data

ney i man	elai Batt	•	
(Rs Bn)	FY23	FY24E	FY25E
Revenue	80.8	90.3	98.8
EBITDA	11.1	12.0	18.6
Net Profit	0.5	2.7	9.8
Total Assets	137.3	141.3	150.8
ROCE (%)	4%	7%	9%
ROE (%)	0%	2%	9%

Source: Company, Keynote Capitals Ltd.

**Chirag Maroo,** Research Analyst Chirag@keynotecapitals.net

# ZEEL | Company Update

Apart from this, Sony was also going to infuse ~\$1.5 Bn in the merged entity, which could have been utilized behind content acquisition/development to combat competition.

Now that the merger has been called off, the expected improvement in the Company's financial position due to ~\$1.5 Bn cash infusion by CMEPL will not take place. This leaves ZEEL only with ~Rs. 5.7 Bn worth of cash and bank as of Q2 FY24, along with its cash generation ability of Rs. 7-8 Bn per annum to invest in acquiring/developing new content. In addition to this, ZEEL will now have to fight all pending litigations on its own, including an added litigation against CMEPL and BEPL.

## Can ZEEL survive on its own?

Though ZEEL may not struggle for its survival, the Company's current financial position indicates that it will find it difficult to simultaneously manage litigations, new content acquisition/development and fighting OTT giants like Amazon, Jio Cinema, Netflix, etc. In addition to this, apprehensions about low promoter holding and weak corporate governance will again erupt strongly as the perception around improvement in governance with CMEPL owning the majority stake in the merger entity will not hold true anymore.

## Avenues available with ZEEL

Currently, ZEEL has two choices: a) continue to operate on its own and b) explore a merger with a peer. No matter what choice the Company takes, the following two things will continue to challenge the smooth progress and valuation rating of ZEEL.

- 1. Mr. Punit Goenka being part of the active management/Board.
- 2. Ongoing litigations with multiple parties, including CMEPL and BEPL.

# **View & Valuation**

Owing to multiple reasons, including weak financial positioning, weak corporate governance in the absence of CMEPL's involvement and the steep price fall post the merger-cancellation news, we downgrade ZEEL from BUY to a NEUTRAL rating with a target price of Rs. 174 (17x FY25E EPS i.e., 30% discount to 5-year median PE). Our estimates indicate that due to the merger being called off, the exceptional expense that was significantly impacting ZEEL's PAT will go down to NIL, resulting in a significant improvement in PAT. However, we continue to closely monitor development around litigations and will revisit our estimates in case of significantly negative developments.

# KEYNOTE

# **Financial Statement Analysis**

Income Statement					
Y/E Mar, Rs. Mn	FY22	FY23	FY24E	FY25E	FY26E
Net Sales	81,857	80,879	90,342	98,780	1,09,466
Growth %		-1%	12%	9%	11%
Operational Expenses	40,418	44,686	49,688	49,390	54,733
Employee Expenses	8,261	8,238	9,202	10,061	10,947
Other Expenses	15,413	16,886	19,424	20,744	21,893
EBITDA	17,766	11,069	12,029	18,585	21,893
Growth %		-38%	9%	55%	18%
Margin%	22%	14%	13%	19%	20%
Depreciation	2,213	3,128	3,561	3,877	4,194
EBIT	15,554	7,941	8,467	14,708	17,699
Growth %		-49%	7%	74%	20%
Margin%	19%	10%	9%	15%	16%
Interest Paid	438	702	846	705	705
Other Income & exceptional	-132	-2,558	-2,000	800	800
PBT	14,984	4,681	5,621	14,803	17,794
Тах	4,448	2,167	1,686	5,033	6,050
РАТ	10,537	2,514	3,935	9,770	11,744
Others (Minorities, Associates)	1	-1	-1	-1	-1
Loss from Discontinued					
Operations	-980	-2,036	-1,219	0	0
Net Profit	9,558	477	2,715	9,769	11,743
Growth %		-95%	469%	260%	20%
Shares (Mn)	960.5	960.5	960.5	960.5	960.5
EPS	10.04	0.50	2.83	10.17	12.23

Balance Sheet					
Y/E Mar, Rs. Mn	FY22	FY23	FY24E	FY25E	FY26E
Cash, Cash equivalents & Bank	12,733	8,040	4,456	9,711	11,588
Current Investments	242	0	0	0	0
Debtors	17,375	16,088	18,068	18,768	20,799
Inventory	63,862	73,079	79,501	83,963	93,046
Short Term Loans & Advances	0	0	0	0	0
Other Current Assets	17,261	15,066	15,066	15,066	15,066
Total Current Assets	1,11,473	1,12,273	1,17,091	1,27,509	1,40,499
Net Block & CWIP	11,235	13,307	12,456	11,542	10,085
Long Term Investments	1,472	830	829	828	827
Other Non-current Assets	8,216	10,873	10,873	10,873	10,873
Total Assets	1,32,396	1,37,284	1,41,249	1,50,752	1,62,283
Creditors	13,719	17,494	18,068	19,756	21,893
Provision	119	135	135	135	135
Short Term Borrowings	14	19	19	19	19
Other Current Liabilities	8,321	8,888	8,888	8,888	8,888
Total Current Liabilities	22,172	26,536	27,110	28,798	30,935
Long Term Debt	21	40	40	40	40
Deferred Tax Liabilities	0	0	0	0	0
Other Long Term Liabilities	1,575	3,489	3,489	3,489	3,489
Total Non Current Liabilities	1,596	3,529	3,529	3,529	3,529
Paid-up Capital	961	961	961	961	961
Reserves & Surplus	1,07,667	1,06,258	1,09,649	1,17,464	1,26,858
Shareholders' Equity	1,08,628	1,07,219	1,10,610	1,18,425	1,27,819
Non Controlling Interest	0	0	0	0	0
Total Equity & Liabilities	1,32,396	1,37,284	1,41,249	1,50,752	1,62,283

Source: Company, Keynote Capitals Ltd. estimates

Cash Flow					
Y/E Mar, Rs. Mn	FY22	FY23	FY24E	FY25E	FY26E
Pre-tax profit	14,984	4,681	5,621	14,803	17,794
Discontinued Operations	-830	-2,069	0	0	0
Adjustments	2,419	5,294	3,607	3,782	4,099
Change in Working Capital	-9,638	-2,722	-7,828	-3,474	-8,976
Total Tax Paid	-4,965	-3,893	-1,686	-5,033	-6,050
Cash flow from operating					
Activities	2,800	1,291	-286	10,078	6,867
Net Capital Expenditure	-2,286	-2,412	-2,710	-2,963	-2,737
Change in investments	7,840	-7	0	0	0
Other investing activities	217	403	0	0	0
Cash flow from investing					
activities	5,771	-2,016	-2,710	-2,963	-2,737
Equity raised / (repaid)	-4,034	0	0	0	0
Debt raised / (repaid)	9	24	0	0	0
Dividend (incl. tax)	-2,850	-2,882	-543	-1,954	-2,349
Other financing activities	-279	-1,224	-846	-705	-705
Cash flow from financing					
activities	-7,154	-4,082	-1,389	-2,659	-3,054
Net Change in cash	1,417	-4,807	-4,385	4,456	1,077

### **Valuation Ratios** FY22 FY23 FY24E FY25E FY26E Per Share Data EPS 10 0 3 10 12 Growth % -95% 469% 260% 20% Book Value Per Share 113 112 115 123 133 **Return Ratios** Return on Assets (%) 8% 0% 2% 7% 8% Return on Equity (%) 9% 0% 2% 9% 10% Return on Capital Employed (%) 9% 4% 7% 9% 10% **Turnover Ratios** Asset Turnover (x) 0.6 0.6 0.6 0.7 0.7 Sales / Gross Block (x) 3.2 2.9 2.8 2.8 2.9 Working Capital / Sales (x) 104% 108% 97% 96% 95% Receivable Days 82 76 68 69 66 604 590 Inventory Days 532 559 560 **Liquidity Ratios** Current Ratio (x) 4.5 5.0 4.2 4.3 4.4 Interest Coverage Ratio (x) 36.4 12.4 11.0 22.0 26.2 Total Debt to Equity 0.0 0.0 0.0 0.0 0.0 Net Debt to Equity -0.1 -0.1 0.0 -0.1 -0.1 Valuation PE (x) 28.7 427.0 84.3 23.4 19.5 Earnings Yield (%) 3% 0% 1% 4% 5% Price to Sales (x) 2.3 3.4 2.5 2.5 2.1 Price to Book (x) 2.5 1.9 2.1 1.9 1.8 EV/EBITDA (x) 14.9 18.0 18.4 11.6 9.9 EV/Sales (x) 2.2 2.0 3.2 2.5 2.4

# ZEEL | Company Update

# KEYNOTE

# **KEYNOTE Rating History**

Date	Rating	Market Price at Recommendation	Upside/Downside
3 <sup>rd</sup> February 2023	BUY	221	+14%
14 <sup>th</sup> February 2023	BUY	216	+17%
29 <sup>th</sup> May 2023	BUY	193	+25%
11 <sup>th</sup> August 2023	BUY	271	+17%
13 <sup>th</sup> November 2023	BUY	252	+15%
1 <sup>st</sup> February 2024	NEUTRAL	170	+2%

# ZEEL | Company Update

# KEYNOTE

# **Rating Methodology**

Rating Criteria		
BUY	Expected positive return of > 10% over 1-year horizon	
NEUTRAL	Expected positive return of > 0% to < 10% over 1-year horizon	
REDUCE	Expected return of < 0% to -10% over 1-year horizon	
SELL	Expected to fall by >10% over 1-year horizon	
NOT RATED (NR)/UNDER REVIEW (UR)/COVERAGE SUSPENDED (CS)	Not covered by Keynote Capitals Ltd/Rating & Fair value under Review/Keynote Capitals Ltd has suspended coverage	

# **Disclosures and Disclaimers**

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Keynote Capitals Ltd. (KCL) is a SEBI Registered Research Analyst having registration no. INH000007997. KCL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. Details of associate entities of Keynote Capitals Limited are available on the website at <a href="https://www.keynotecapitals.com/associate-entities/">https://www.keynotecapitals.com/associate-entities/</a>

KCL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of KCL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

KCL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that KCL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

Details of pending Enquiry Proceedings of KCL are available on the website at https://www.keynotecapitals.com/pending-enquiry-proceedings/

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of KCL or its associates maintains arm's length distance with Research Team as all the activities are segregated from KCL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

# **Regional Disclosures (outside India)**

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject KCL & its group companies to registration or licensing requirements within such jurisdictions. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

# Specific Disclosure of Interest statement for subjected Scrip in this document:

Financial Interest of Research Entity [KCL] and its associates; Research Analyst and its Relatives	NO
Any other material conflict of interest at the time of publishing the research report by Research Entity [KCL] and its associates; Research Analyst and its Relatives	NO
Receipt of compensation by KCL or its Associate Companies from the subject company covered for in the last twelve months; Managing/co-managing public offering of securities in the last twelve months; Receipt of compensation towards Investment banking/merchant banking/brokerage services in the last twelve months; Products or services other than those above in connection with research report in the last twelve months; Compensation or other benefits from the subject company or third party in connection with the research report in the last twelve months.	NO
Whether covering analyst has served as an officer, director or employee of the subject company covered	NO
Whether the KCL and its associates has been engaged in market making activity of the Subject Company	NO
Whether the Research Entity [KCL] and its associates; Research Analyst and its Relatives, have actual/beneficial ownership of 1% or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance.	NO

### The associates of KCL may have:

- financial interest in the subject company

-actual/beneficial ownership of 1% or more securities in the subject company

-received compensation/other benefits from the subject company in the past 12 months

-other potential conflict of interests with respect to any recommendation and other related information and opinions.; however, the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of KCL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

-acted as a manager or co-manager of public offering of securities of the subject company in past 12 months

-be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)

-received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

The associates of KCL has not received any compensation or other benefits from third party in connection with the research report.

Above disclosures includes beneficial holdings lying in demat account of KCL which are opened for proprietary investments only. While calculating beneficial holdings, it does not consider demat accounts which are opened in name of KCL for other purposes (i.e. holding client securities, collaterals, error trades etc.). KCL also earns DP income from clients which are not considered in above disclosures.

## **Analyst Certification**

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

### **Terms & Conditions:**

This report has been prepared by KCL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of KCL. The report is based on the facts, figures and information that are believed to be true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. KCL will not treat recipients as customers by virtue of their receiving this report

### **Disclaimer:**

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative product as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. KCL, its associates, their directors and the employees may from time to time, effect or have affected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. KCL, its associates, their directors and the employees may from time to time invest in any discretionary PMS/AIF Fund and those respective PMS/AIF Funds may affect or have effected any transaction in for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of KCL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject KCL to any registration or licensing requirement within such jurisdiction.

# KEYNOTE

The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt KCL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold KCL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

### Keynote Capitals Limited (CIN: U67120MH1995PLC088172)

Compliance Officer: Mr. Jairaj Nair; Tel: 022-68266000; email id: jairaj@keynoteindia.net

Registered Office: 9th Floor, The Ruby, Senapati Bapat Marg, Dadar West, Mumbai – 400028, Maharashtra. Tel: 022 – 68266000.

SEBI Regn. Nos.: BSE / NSE (CASH / F&O / CD): INZ000241530; DP: CDSL- IN-DP-238-2016; Research Analyst: INH000007997

For any complaints email at kcl@keynoteindia.net

General Disclaimer: Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on <u>www.keynotecapitals.com</u>; Investment in securities market are subject to market risks, read all the related documents carefully before investing.